Paper Details

  1. Home
  2. Paper Details

Phase III clinical pharmacology study of tolvaptan.

Author: , HirayamaAtsushi, HoriMasatsugu, InomataTakayuki, IzumiTohru, MatsuzakiMasunori

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Tolvaptan, a vasopressin V2-receptor antagonist, demonstrated diuretic effects and body weight loss in Japanese heart failure (HF) patients with volume overload. The effects were dose-dependent, with 15 mg/day resulting in a greater increase in urine volume and weight loss compared to 7.5 mg/day. Tolvaptan enhanced water diuresis without affecting blood electrolytes.
Paper Details　
Original Abstract of the Article :
PURPOSE: This study aimed to investigate the pharmacokinetics, pharmacodynamics, efficacy and safety of tolvaptan, an orally effective vasopressin V2-receptor antagonist. METHODS: This was a multicenter, randomized, double-blind, parallel group study. Tolvaptan was administered at 7.5 or 15 mg, in ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s10557-011-6349-x

データ提供：米国国立医学図書館（NLM）

Phase III Clinical Pharmacology Study of Tolvaptan

In the realm of medicine, treating heart failure is a challenging endeavor. This phase III clinical trial investigated the pharmacokinetics, pharmacodynamics, efficacy, and safety of tolvaptan, a novel vasopressin V2-receptor antagonist, in Japanese heart failure patients with volume overload.

Tolvaptan: A Promising Approach to Volume Overload

The study found that tolvaptan, when administered at doses of 7.5 mg or 15 mg in combination with furosemide, increased urine volume and facilitated weight loss in a dose-dependent manner. Notably, tolvaptan enhanced water diuresis without affecting blood electrolyte levels, suggesting its potential as a safe and effective treatment option for volume overload in heart failure patients.

A Dose-Dependent Effect: Navigating the Desert of Treatment Options

The study revealed that the diuretic effects of tolvaptan were more pronounced at a higher dose (15 mg). This finding highlights the importance of optimizing dosage for individual patients to achieve the best therapeutic outcomes. Think of it as navigating a desert with different oasis sizes, where each oasis represents a different dose of medication, and choosing the oasis that best fits your needs.

Dr.Camel's Conclusion

This phase III study provides compelling evidence for the efficacy and safety of tolvaptan in managing volume overload in heart failure patients. The dose-dependent effects suggest that tailored treatment plans are essential to optimize therapeutic outcomes and enhance patient well-being.
Date :
  1. Date Completed 2012-04-10
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

22120094

DOI: Digital Object Identifier

10.1007/s10557-011-6349-x

Related Literature

Article Analysis
・Effects of tolvaptan (low blood sodium)
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.